Filtered By:
Cancer: Lymphoma
Procedure: Transplants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1940 results found since Jan 2013.
Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment
Autoimmunity. 2023 Dec;56(1):2259126. doi: 10.1080/08916934.2023.2259126. Epub 2023 Sep 22.ABSTRACTA novel therapeutic regimen showed that the oncolytic type II herpes simplex virus (oHSV2) was able to prevent colorectal cancer growth, recurrence, and metastasis. However, no study has yet explored whether oHSV2 has an impact on the development of diffuse large B-cell lymphoma (DLBCL). We chose the clinical chemotherapeutic drug doxorubicin (DOX) as a positive control to evaluate the effect of oHSV2 infection on the apoptotic, invasive, and proliferative capacity of DLBCL cells. We next further explored the therapeutic effi...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Jingbo Zhang Yiwei Guo Huiying Fang Xiuchen Guo Lina Zhao Source Type: research
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.ABSTRACTHepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving chemotherapy, especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation. Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver. The expression of these silent genomes is controlled by the immune system. Suppression or ablation of immune cells, most imp...
Source: World Journal of Gastroenterology : WJG - September 21, 2023 Category: Gastroenterology Authors: Joyce Wing Yan Mak Alvin Wing Hin Law Kimmy Wan Tung Law Rita Ho Carmen Ka Man Cheung Man Fai Law Source Type: research
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Clinical analysis of bacterial infection characteristics in lymphoma patients with high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation-a single-centered retrospective study
CONCLUSION: High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDT/AHSCT) is used to treat lymphoma. Although AHSCT has made considerable strides and become safer, HDT-AHSCT infection continues to be a leading cause of morbidity and mortality associated with transplantation.PMID:37718527 | DOI:10.2174/1386207326666230915115056
Source: Combinatorial Chemistry and High Throughput Screening - September 18, 2023 Category: Chemistry Authors: Dan-Hui Sun Di Mei Xiao-Qin Yaoz Yi-Hui Rong Gui-Qiang Wang Source Type: research
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
CONCLUSION: Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT. Additional studies are needed to fully elucidate the suitability of CAR-T cell therapy in the post-alloSCT setting.PMID:37716872 | DOI:10.1016/j.clml.2023.08.012
Source: Clinical Lymphoma and Myeloma - September 16, 2023 Category: Cancer & Oncology Authors: Myo Htut Binod Dhakal Adam D Cohen Thomas Martin Jesus G Berdeja Saad Z Usmani Mounzer Agha Carolyn C Jackson Deepu Madduri William Deraedt Enrique Zudaire Tzu-Min Yeh Xiaoying Xu Lida Pacaud Muhammad Akram Sundar Jagannath Source Type: research
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen
CONCLUSIONS: BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.PMID:37708877 | DOI:10.1159/000533944
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Leona A Holmberg David G Maloney Laura Connelly-Smith Source Type: research
